Ken Griffin Aligos Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.35 - $1.07 $35 - $107
100 Added 50.0%
300 $0
Q1 2024

May 15, 2024
BUY
$0.64 - $1.13 $128 - $225
200 New
200 $0
Q4 2022

Feb 14, 2023
BUY
$0.89 - $28.0 $89 - $2,800
100 New
100 $0

Others Institutions Holding ALGS

# of Institutions
1
Shares Held
227K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $1.3B
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email